

## CD20 [L26] - 167Er

**Catalog:** 716701


**Clone:** L26

**Isotype:** Mouse IgG2a


**Reactivity:** Human\*

**Application:** MIBI-FFPE


**Storage:** Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C




**IHC:** CD20 staining of FFPE human tonsil



**MIBI:** CD20 staining (cyan) of FFPE human tonsil, costained with dsDNA (magenta)



**IHC:** CD20 staining of FFPE human thymus



**MIBI:** CD20 staining (cyan) of FFPE human thymus, costained with dsDNA (magenta)

### Background

CD20 is an activated-glycosylated phosphoprotein expressed on B cells from late pro-B cells through memory B cells but is absent from plasma cells. CD20 is involved in the transport of calcium and calcium-dependent intracellular signaling pathways. Anti-CD20 therapy is used to treat diseases with a B cell component such as B-cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis (RA).

### Validation

Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIScope analysis using the appropriate positive and negative tissue field of views.

### Recommended Usage

Human FFPE: 0.5 ug/mL dilution. For optimal results, the antibody should be titrated for each desired application.

### References

Walport M, Murphy K, Janeway C, Travers PJ (2008). *Janeway's Immunobiology* (7th ed.). New York: Garland Science.

Payandeh, Z., Bahrami, A. A., Hoseinpoor, R., Mortazavi, Y., Rajabibazl, M., Rahimpour, A., Taromchi, A. H., Khalil, S. The applications of anti-CD20 antibodies to treat various B cells disorders. *Biomedicine & Pharmacotherapy*. 2019; **109**:2415-2426.

\* Conjugate tested on human tissue.